Rituximab Combined with Autologous Peripheral Blood Stem Cell Transplantation Improve Therapeutic Effects of Chemotherapy in Pediatric Patients with Burkitt's Lymphoma

Department of Pediatrics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, 510120, China.
Journal of Tropical Pediatrics (Impact Factor: 1.26). 10/2010; 56(5):337-41. DOI: 10.1093/tropej/fmp137
Source: PubMed


We report on 2 children with Burkitt's lymphoma accompanied by extensive extranodal involvement treated with chemotherapy
and Rituximab in combination with autologous peripheral blood stem cell transplantation (Auto-PBSCT) regimens. No obvious
side effects could be seen during the Rituximab therapy. Both children achieved complete remission with no relapse after being
followed up for 4.3 and 4 years, respectively. Our limited experience show that Rituximab in combination with chemotherapy
and Auto-PBSCT might have better therapeutic effects on Burkitt's lymphoma of children and the side effects of Rituximab therapy
is minimal and can be well tolerated.

4 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Burkitt lymphoma (BL) is an aggressive B-cell neoplasm with an extremely short doubling time that mainly affects children and young adults. Despite having several characteristic features, none is entirely specific for BL and the differential diagnosis may include diffuse large B-cell lymphoma (DLBCL), B lymphoblastic leukemia/lymphoma, and B-cell lymphoma unclassifiable with features intermediate between DLBCL and BL. We outline a practical approach to establish a diagnosis of BL and distinguish it from other high-grade B-cell malignancies. We pay particular attention to B-cell lymphomas with features intermediate between DLBCL and BL, a new diagnostic category in the 2008 World Health Organization classification system that provides a framework for categorizing challenging cases not meeting diagnostic criteria for either “classic” BL or DLBCL.
    No preview · Article · Dec 2010 · Surgical Pathology Clinics
  • [Show abstract] [Hide abstract]
    ABSTRACT: On reviewing current protocols for procurement of autologous Haematopoietic Progenitor Cells by apheresis—commonly known as “Peripheral Blood Stem Cells (PBSC)” or “Peripheral Blood Progenitor cells (PBPC)”, but more correctly termed “HPC-A” using FACT/JACIE terminology [1]—it is immediately striking how diverse current clinical practice actually is. Individual centres, even within one country or even within one city, may be using different mobilisation regimes, different apheresis platforms (i.e. different machines), different “trigger” peripheral blood markers for apheresis and different threshold levels of these markers, different target CD34+ cell doses and different protocols for how much of the patient’s blood to process during each apheresis. Although plerixafor undoubtedly represents a significant advance in autologous HPC-A procurement, the challenge for many centres has been incorporating the drug into very diverse local protocols. This chapter aims to review published experience regarding how plerixafor may best be incorporated into existing apheresis protocols. However, given the logistical obstacles to practising “evidence-based Apheresis Medicine” and the general lack of randomised controlled studies in this subspecialty [2, 3], this chapter is necessarily a rather subjective overview, and the author discusses published and unpublished experience from his own centre in addition to the existing published experience from elsewhere.
    No preview · Chapter · Jan 2012
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Burkitt lymphoma (BL) is a highly aggressive B-cell lymphoma with rapid proliferation. It has become evident that miRNAs are involved in hematopoietic malignancies. This study was undertaken to investigate the miRNA expression patterns of pediatric intestinal BL tissues. Methods We collected 28 BL patients and 8 reactive lymphoid hyperplasia (RLH) samples. miRNA expression profiling was performed in BL and RLH tissues to identify BL-related miRNAs,which was further analyzed by qRT-PCR and miRNA-ISH. In addition, immunohistochemistry (IHC) and western blot were used to define the protein targets of the BL-related miRNAs. Furthermore, we evaluated cell growth status by using Methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay in Raji cell line, which was transected with the BL-related miRNA mimics or inhibitors. Results MiRNA expression profiling showed that miR-150 had an extremely decrease expression levels in BL patients. In both ISH and qRT-PCR analysis, BL had reduced levels of miR-150 expression compared with RLH. But there is no significant correlation of miR-150 expression and EBV status in BL. Moreover, IHC and western blotting defined that c-myb and Survivin are the protein targets of miR-150. Re-expression of miR-150 reduced proliferation of Raji cells. Conclusions Deregulation of miR-150 may be useful as a diagnostic tool in BL, based on miRNA profile screening, qRT-PCR and miRNA-ISH. miR-150 plays an important role in BL by targeting of c-Myb and Survivin.Re-expression of miR-150 reduced proliferation of Raji cells, which suggest it as a promising novel candidate for tumor treatment.
    No preview · Article · Apr 2014 · Experimental and Molecular Pathology